NAPLEX 2026 — Infectious Diseases Practice Exam 2

Thirty-nine single-best-answer items with five options, eight select-all-that-apply items and three numeric fill-in items. Tuberculosis across latent-infection testing and regimen choice, standard four-drug therapy and when treatment runs to nine months, hepatotoxicity and adverse-effect thresholds, rifamycin drug interactions, tuberculous meningitis, drug-resistant disease and infection control; invasive fungal infection including candidemia and step-down therapy, invasive aspergillosis, cryptococcal meningitis, mucormycosis, Candida auris, and the azole, echinocandin and amphotericin safety problems that come with them; the herpes-family antivirals including dose adjustment in kidney impairment, antiviral neurotoxicity, marrow suppression and resistant infection; influenza antiviral selection in pregnancy, asthma and delayed presentation; hepatitis B serology interpretation, screening, treatment thresholds and vaccine non-response; vancomycin exposure monitoring including continuous infusion; aminoglycoside, daptomycin, linezolid, fluoroquinolone and trimethoprim/sulfamethoxazole safety; resistant organisms from inducible AmpC to intrinsically resistant non-fermenters; and the calculations behind an adjusted-body-weight aminoglycoside dose, a proportional vancomycin exposure adjustment and an antidote dose in overdose.